EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Raltitrexed in Hepatocellular Carcinoma: Mechanistic Rationale and Clinical Evidence from Arterial-Based Therapies

Xiaoli Jia iD, Yusi Ding iD, Yuanyi Chen, Wenjun Wang

Journal of Hepatocellular Carcinoma · 2026-04 · Volume 13 · 1-9

DOI: 10.2147/jhc.s601493 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-04. Verfasst von Xiaoli Jia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage, resulting in limited eligibility for curative therapies and suboptimal outcomes with systemic treatment alone. Locoregional arterial therapies, including transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC), therefore remain integral components of treatment for unresectable HCC. Raltitrexed is a quinazoline antifolate that directly and specifically inhibits thymidylate synthase, leading to sustained suppression of DNA synthesis. Compared with 5-fluorouracil, raltitrexed offers distinct pharmacokinetic and practical advantages, including prolonged intracellular retention and a short infusion schedule. Originally developed for colorectal cancer, raltitrexed has been increasingly incorporated into arterial-based treatment strategies for HCC over the past decade. Accumulating evidence from retrospective studies, prospective single-arm trials, and limited comparative analyses suggests that raltitrexed-based regimens demonstrate meaningful antitumor activity in conventional and drug-eluting bead TACE, as well as in oxaliplatin-based HAIC, with objective response rates, disease control, and survival outcomes comparable to established chemotherapy protocols. Notably, raltitrexed-based HAIC substantially reduces infusion time relative to fluorouracil-based regimens, improving treatment convenience without compromising efficacy. More recently, raltitrexed-containing HAIC has been explored in combination with targeted therapy and immune checkpoint inhibitors, yielding encouraging response rates and survival signals in patients with advanced disease. Overall, raltitrexed represents a rational and increasingly utilized component of arterial-based therapies for unresectable HCC. However, current evidence is predominantly derived from retrospective and single-arm studies, and well-designed randomized trials and biomarker-driven approaches are required to define its optimal role in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

hepatic arterial infusion chemotherapyhepatocellular carcinomalocoregional therapyraltitrexedtransarterial chemoembolization

Autor:innen und Institutionen

  • Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.

ORCID-Profile: Xiaoli Jia, Yusi Ding

Zitieren

APA

Jia, X., Ding, Y., Chen, Y., & Wang, W. (2026). Raltitrexed in Hepatocellular Carcinoma: Mechanistic Rationale and Clinical Evidence from Arterial-Based Therapies. Journal of Hepatocellular Carcinoma, Volume 13, 1-9. https://doi.org/10.2147/jhc.s601493

Vancouver

Jia X, Ding Y, Chen Y, Wang W. Raltitrexed in Hepatocellular Carcinoma: Mechanistic Rationale and Clinical Evidence from Arterial-Based Therapies. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-9. doi:10.2147/jhc.s601493

BibTeX
@article{Jia2026,
  author = {Jia, Xiaoli and Ding, Yusi and Chen, Yuanyi and Wang, Wenjun},
  title = {Raltitrexed in Hepatocellular Carcinoma: Mechanistic Rationale and Clinical Evidence from Arterial-Based Therapies},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  volume = {Volume 13},
  pages = {1--9},
  doi = {10.2147/jhc.s601493}
}
Kostenlos starten →